These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35362122)

  • 1. Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
    Adomi M; Ray A
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1069. PubMed ID: 35362122
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.
    Selinger CP; Lenti MV; De Silvestri A
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1070-1071. PubMed ID: 35362123
    [No Abstract]   [Full Text] [Related]  

  • 3. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.
    Huff-Hardy K; Bedair M; Vazquez R; Burstein E
    Inflamm Bowel Dis; 2017 Oct; 23(10):E49. PubMed ID: 28858074
    [No Abstract]   [Full Text] [Related]  

  • 5. The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
    Kassouri L; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Dig Liver Dis; 2020 Oct; 52(10):1148-1155. PubMed ID: 32828693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P; Moćko P
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
    Biemans VBC; Hoentjen F; Pierik MJ
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1255-1256. PubMed ID: 33016547
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Aliment Pharmacol Ther; 2020 May; 51(10):948-957. PubMed ID: 32249966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Liu K; Cai F; Huang J
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1253-1254. PubMed ID: 33016544
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
    Holko P; Kawalec P; Pilc A
    Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
    Hudson J; Herfarth HH; Barnes EL
    Aliment Pharmacol Ther; 2020 Sep; 52(5):906. PubMed ID: 32852815
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
    Tursi A; Mocci G; Picchio M; Elisei W; Maconi G
    Aliment Pharmacol Ther; 2021 Apr; 53(7):859-860. PubMed ID: 33709395
    [No Abstract]   [Full Text] [Related]  

  • 15. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
    Kopylov U
    Aliment Pharmacol Ther; 2020 Sep; 52(5):907. PubMed ID: 32852835
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
    Bertani L; Antonioli L; Blandizzi C
    Aliment Pharmacol Ther; 2020 Aug; 52(4):751-752. PubMed ID: 32886387
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    MacDonald JK; Nguyen TM; Khanna R; Timmer A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
    Biemans VBC; Hoentjen F; Pierik MJ
    Aliment Pharmacol Ther; 2020 Aug; 52(4):753-754. PubMed ID: 32886363
    [No Abstract]   [Full Text] [Related]  

  • 20. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.